A recent study demonstrated that the combination of CA19.9 (a pancreatic tumor-associated antigen used in clinic) with MMP-7 and connective tissue growth factor (CCN2) differentiates PDAC patients from healthy patients [391], whereas a panel composed of CCN2, plasminogen (PGL), fibronectin, collagen IV and CA19.9 distinguishes PDAC patients from patients with chronic pancreatitis [391]. This evidence concerns the gene FN1 and pancreatic neoplasm.